P&K SKIN RESEARCH CENTER CO., LTD. Financials P&K Skin Research Center Co., Ltd.
Equities
A347740
KR7347740003
Business Support Services
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,995 KRW | +1.01% |
|
+1.18% | +21.75% |
Valuation
| Fiscal Period: December | 2022 | 2023 |
|---|---|---|
| Capitalization 1 | 91,082 | 73,826 |
| Enterprise Value (EV) 1 | 34,360 | 29,807 |
| P/E ratio | 12.7 x | 15.3 x |
| Yield | 1.15% | 1.22% |
| Capitalization / Revenue | 5.07 x | 4.97 x |
| EV / Revenue | 1.91 x | 2.01 x |
| EV / EBITDA | 4.83 x | 9.57 x |
| EV / FCF | - | -9,948,194 x |
| FCF Yield | - | -0% |
| Price to Book | 1.29 x | 0.99 x |
| Nbr of stocks (in thousands) | 30,011 | 30,011 |
| Reference price 2 | 3,035 | 2,460 |
| Announcement Date | 3/20/24 | 3/20/24 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 |
|---|---|---|
| Net sales 1 | 17,957 | 14,843 |
| EBITDA 1 | 7,108 | 3,114 |
| EBIT 1 | 5,640 | 1,379 |
| Operating Margin | 31.41% | 9.29% |
| Earnings before Tax (EBT) 1 | 8,190 | 5,357 |
| Net income 1 | 7,130 | 4,813 |
| Net margin | 39.71% | 32.43% |
| EPS 2 | 239.1 | 160.5 |
| Free Cash Flow | - | -2,996 |
| FCF margin | - | -20.19% |
| FCF Conversion (EBITDA) | - | - |
| FCF Conversion (Net income) | - | - |
| Dividend per Share 2 | 35.00 | 30.00 |
| Announcement Date | 3/20/24 | 3/20/24 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 |
|---|---|
| Net sales 1 | 3.823 |
| EBITDA | - |
| EBIT 1 | 1.002 |
| Operating Margin | 26.22% |
| Earnings before Tax (EBT) | - |
| Net income 1 | 1.316 |
| Net margin | 34.41% |
| EPS | - |
| Dividend per Share | - |
| Announcement Date | 11/15/21 |
1KRW in Billions
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 |
|---|---|---|
| Net Debt 1 | - | - |
| Net Cash position 1 | 56,722 | 44,019 |
| Leverage (Debt/EBITDA) | - | - |
| Free Cash Flow | - | -2,996 |
| ROE (net income / shareholders' equity) | - | 6.48% |
| ROA (Net income/ Total Assets) | - | 1.13% |
| Assets 1 | - | 424,327 |
| Book Value Per Share 2 | 2,359 | 2,493 |
| Cash Flow per Share 2 | 166.0 | 329.0 |
| Capex 1 | 1,230 | 1,526 |
| Capex / Sales | 6.85% | 10.28% |
| Announcement Date | 3/20/24 | 3/20/24 |
1KRW in Million2KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +21.75% | 64.99M | |
| +15.80% | 17.6B | |
| -12.60% | 2.67B | |
| -19.65% | 2.64B | |
| -26.54% | 1.86B | |
| -10.33% | 1.07B | |
| -8.09% | 1.05B | |
| +6.12% | 879M | |
| +1.24% | 764M | |
| -18.81% | 757M |
- Stock Market
- Equities
- A347740 Stock
- Financials P&K Skin Research Center Co., Ltd.
